BALANCE SHEET AS AT MARCH 31, 2013

March 31, 2013

in Lacs
EQUITY AND LIABILITIES
Shareholders funds
Share capital
Reserves and surplus
Total
Non-current liabilities
Long-term borrowings
Deferred tax liabilities (net)
Other long term liabilities
Long-term provisions
Total
Current liabilities
Short-term borrowings
Trade payables
Other current liabilities
Short-term provisions
Total
TOTAL
ASSETS
Non-current assets
Fixed assets
Tangible assets
Intangible assets
Capital work-in-progress
(i) Total
(ii) Non-current investments
(iii) Long-term loans and advances
(iv) Other non-current assets
Total (i)+(ii)+(iii)+(iv)
Current assets
Current investments
Inventories
Trade receivables
Cash and bank balances
Short-term loans and advances
Other current assets
Total
TOTAL

March 31, 2012

in Lacs

40,953.37
279,551.86
320,505.23

40,950.61
279,509.56
320,460.17

69,743.33
31.84
1,527.02
704.11
72,006.30

67,978.23
0
7,641.56
466.12
76,085.91

30,056.49
4,734.31
19,758.32
765.76
55,314.88
447,826.41

42,266.05
4,637.61
5,882.22
417.27
53,203.15
449,749.23

11,454.52
304.24
7,294.23
19,052.99
210,268.46
83,875.24
17,428.19
330,624.88

8,321.72
130.32
4,865.09
13,317.13
231,008.17
50,331.93
1,664.97
296,322.20

30,319.71
484.86
9,305.03
10,857.96
65,034.88
1,199.09
117,201.53
447,826.41

0
425.29
6,249.50
1,486.50
139,253.43
6,012.31
153,427.03
449,749.23

148,966.83

4,115.07

357,383.04

BALANCE SHEET AS AT MARCH 31, 2013

March 31, 2013
in Lacs
EQUITY AND LIABILITIES
Shareholders funds
Share capital
Reserves and surplus
Total
Non-current liabilities
Long-term borrowings
Deferred tax liabilities (net)
Other long term liabilities
Long-term provisions
Total
Current liabilities
Short-term borrowings
Trade payables
Other current liabilities
Short-term provisions
Total
TOTAL
ASSETS
Non-current assets
Fixed assets
Tangible assets
Intangible assets
Capital work-in-progress
(i) Total
(ii) Non-current investments
(iii) Long-term loans and advances
(iv) Other non-current assets
Total (i)+(ii)+(iii)+(iv)
Current assets
Current investments
Inventories
Trade receivables
Cash and bank balances
Short-term loans and advances
Other current assets
Total
TOTAL

40,953.37
279,551.86
320,505.23

9.14%
62.42%
71.57%

69,743.33
31.84
1,527.02
704.11
72,006.30

15.57%
0.01%
0.34%
0.16%
16.08%

30,056.49
4,734.31
19,758.32
765.76
55,314.88
447,826.41

6.71%
1.06%
4.41%
0.17%
12.35%
100%

11,454.52
304.24
7,294.23
19,052.99
210,268.46
83,875.24
17,428.19
330,624.88

2.56%
0.07%
1.63%
4.25%
46.95%
18.73%
3.89%
73.83%
0.00%
6.77%
0.11%
2.08%
2.42%
14.52%
0.27%
26.17%
100.00%

30,319.71
484.86
9,305.03
10,857.96
65,034.88
1,199.09
117,201.53
447,826.41

March 31, 2012

in Lacs

40,950.61
279,509.56
320,460.17
67,978.23
0
7,641.56
466.12
76,085.91
42,266.05
4,637.61
5,882.22
417.27
53,203.15
449,749.23

8,321.72
130.32
4,865.09
13,317.13
231,008.17
50,331.93
1,664.97
296,322.20
0
425.29
6,249.50
1,486.50
139,253.43
6,012.31
153,427.03
449,749.23

9.11%
62.15%
71.25%
0.00%
15.11%
0.00%
1.70%
0.10%
16.92%
0.00%
9.40%
1.03%
1.31%
0.09%
11.83%
100.00%

1.85%
0.03%
1.08%
2.96%
51.36%
11.19%
0.37%
65.89%
0.00%
0.00%
0.09%
1.39%
0.33%
30.96%
1.34%
34.11%
100.00%

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2013
March 31, 2013
in Lacs
INCOME
Revenue from operations
Other income
Exceptional items
Total revenue
EXPENDITURE
Purchase of medical consumables and drugs (includes prior period items of ` 0.11 lacs,
Previous year ` 29 lacs)
Increase in inventories of medical consumables and drugs
Employee benefits expense
Other expenses
Total expenses
Earnings before interest, tax, depreciation and amortization (EBITDA)
Finance costs
Profit before tax, depreciation and amortization
Depreciation and amortization expense
Profit before tax
Tax expense:
Current tax (including MAT payable)
Less: MAT credit entitlement
Deferred tax charge
Total tax expenses
Profit for the year
Earnings per share [Nominal value of shares ` 10/- each (Previous year ` 10/- each)
Basic
Diluted

35,297.21
19,056.93
0
54,354.14

10,187.06
-51.39
10,133.14
15,144.46
35,413.27
18,940.87
13,386.47
5,554.40
2,346.83
3,207.57
1,450.85
0
31.84
1,482.69
1,724.88
0.43
0.43

March 31, 2012

in Lacs
28,127.97
12,704.24
18,462.37
59,294.58

7,951.71
-95.56
7,073.50
12,721.55
27,651.20
31,643.38
10,293.40
21,349.98
1,211.44
20,138.54
4,030.45
-4,030.45
0
0.00
20,138.54
4.97
4.97

1894087%
172488%

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2013

INCOME
Revenue from operations
Total revenue
EXPENDITURE
Purchase of medical consumables and drugs (includes prior period items of ` 0.11 lacs,
Previous year ` 29 lacs)
Increase in inventories of medical consumables and drugs
Employee benefits expense
Other expenses
Depreciation and amortization expense
Total expenses
Earnings before interest, tax, depreciation and amortization (EBITDA)
Profit before tax
Tax expense:
Current tax (including MAT payable)
Less: MAT credit entitlement
Deferred tax charge
Total tax expenses
Current Year Income Tax
Tax on Other Income
Tax on Finance costs
Tax on Exceptional items
Net Tax
Net Operating Profit after tax (NOPAT)
NOPAT
Other income (Net of Tax)
Finance costs (Net of Tax)
Profit after tax before exceptional items
Exceptional items (Net of Tax)

Profit for the year

Other income
Finance costs
Exceptional items

Average Total Assets

Average Investments
Operating Assets
return on assets
return on operating assets
Asset turnover
Operating asset turnover

March 31, 2013 March 31, 2012

in Lacs
in Lacs
35,297.21
35,297.21

28,127.97
28,127.97

10,187.06
-51.39
10,133.14
15,144.46
2,346.83
37,760.10

7,951.71
-95.56
7,073.50
12,721.55
1,211.44
28,862.64

-2,462.89
0.00
-2,462.89

-734.67
0.00
-734.67

1,450.85
0
31.84
1,482.69

4,030.45
-4,030.45
0
0.00

1,482.69
6,183.02
4,343.24
0.00
-357.09

0.00
4,121.89
3,339.69
5,990.12
-6,772.31

-2,105.80

6,037.64

-2,105.80
12,873.91
9,043.23
1,724.88

6,037.64
8,582.35
6,953.71
7,666.29

0.00
1,724.88

12,472.25
20,138.54

19,056.93
13,386.47
0

12,704.24
10,293.40
18,462.37

Tax percentage

32.445

448,787.82
235,798.17
212,989.65

403,566.14
192,045.04
211,521.10

0.38%
-0.99%

1.90%
2.85%

7.87%
16.57%

6.97%
13.30%

BALANCE SHEET AS AT MARCH 31, 2013

March 31, 2013
in Lacs
EQUITY AND LIABILITIES
Shareholders funds
Share capital
Reserves and surplus
Total
Non-current liabilities
Long-term borrowings
Deferred tax liabilities (net)
Other long term liabilities
Long-term provisions
Total
Current liabilities
Short-term borrowings
Trade payables
Other current liabilities
Short-term provisions
Total
TOTAL
ASSETS
Non-current assets
Fixed assets
Tangible assets
Intangible assets
Capital work-in-progress
(i) Total
(ii) Non-current investments
(iii) Long-term loans and advances
(iv) Other non-current assets
Total (i)+(ii)+(iii)+(iv)
Current assets
Current investments
Inventories
Trade receivables
Cash and bank balances
Short-term loans and advances
Other current assets
Total
TOTAL

March 31, 2012

in Lacs

40,953.37
279,551.86
320,505.23

40,950.61
279,509.56
320,460.17

69,743.33
31.84
1,527.02
704.11
72,006.30

67,978.23
0
7,641.56
466.12
76,085.91

30,056.49
4,734.31
19,758.32
765.76
55,314.88
447,826.41

42,266.05
4,637.61
5,882.22
417.27
53,203.15
449,749.23

11,454.52
304.24
7,294.23
19,052.99
210,268.46
83,875.24
17,428.19
330,624.88

8,321.72
130.32
4,865.09
13,317.13
231,008.17
50,331.93
1,664.97
296,322.20

30,319.71
484.86
9,305.03
10,857.96
65,034.88
1,199.09
117,201.53
447,826.41

0
425.29
6,249.50
1,486.50
139,253.43
6,012.31
153,427.03
449,749.23

Change
Amount

2.76
42.30
45.06

0%
0%
0%

1,765.10
31.84
-6,114.54
237.99
-4,079.61

3%
-80%
51%
-5%

-12,209.56
96.70
13,876.10
348.49
2,111.73
-1,922.82

-29%
2%
236%
84%
4%
0%

3,132.80
173.92
2,429.14
5,735.86
-20,739.71
33,543.31
15,763.22
34,302.68

38%
133%
50%
43%
-9%
67%
947%
12%

30,319.71
59.57
3,055.53
9,371.46
-74,218.55
-4,813.22
-36,225.50
-1,922.82

14%
49%
630%
-53%
-80%
-24%
0%

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2013
March 31, 2013
in Lacs
INCOME
Revenue from operations
Other income
Exceptional items
Total revenue

35,297.21
19,056.93
0
54,354.14

EXPENDITURE
Purchase of medical consumables and drugs (includes prior period items of ` 0.11 lacs,
Previous year ` 29 lacs)
Increase in inventories of medical consumables and drugs
Employee benefits expense
Other expenses
Total expenses

10,187.06
51.39
10,133.14
15,144.46
35,413.27

Earnings before interest, tax, depreciation and amortization (EBITDA)

Finance costs
Profit before tax, depreciation and amortization

18,940.87
13,386.47
5,554.40

Depreciation and amortization expense

Profit before tax

2,346.83
3,207.57

Tax expense:
Current tax (including MAT payable)
Less: MAT credit entitlement
Deferred tax charge
Total tax expenses

1,450.85
0
31.84
1,482.69

Profit for the year

1,724.88

Earnings per share [Nominal value of shares ` 10/- each (Previous year ` 10/- each)
Basic
Diluted

0.43
0.43

March 31, 2012

Change
in Lacs
Amount
%
28,127.97 7,169.24
12,704.24 6,352.69
18,462.37 -18,462.37
59,294.58 -4,940.44

7,951.71
95.56
7,073.50
12,721.55
27,651.20

25%
50%
-100%
-8%

2,235.35
-44.17
3,059.64
2,422.91
7,762.07

28%
-46%
43%
19%
28%

31,643.38 -12,702.51
10,293.40 3,093.07
21,349.98 -15,795.58

-40%
30%
-74%

1,211.44 1,135.39
20,138.54 -16,930.97

94%
-84%

4,030.45
4,030.45
0
0

-2,579.60
-4,030.45
31.84
1,482.69

-64%
-100%

20,138.54 -18,413.66

-91%

4.97
4.97

-4.54
-4.54

-91%
-91%

Profitability Ratios
Amounts in Rs. Lacs
Ratio

Formula

A Return on Equity

Profit After Tax

Total Shareholders Funds

2012-2013
1,724.88
320,505.23

0.54%

Profit After Tax

Sales

1,724.88
35,297.21

4.89%

C Operating Profit Margin (%)

NOPAT
Sales

(2,105.80)
35,297.21

-5.97%

D Return on Assets

Profit After Tax

Average Total Assets

Net Profit Margin (%) or Return On Sales

Profit margin

Profit After Tax

Sales

Asset Turnover Ratio

Sales
Total Assets

1,724.88
448,787.82

0.38%

1,724.88
35,297.21

4.89%

35,297.21
448,787.82

7.87%

1,724.88

0.54%

* Profit excluding exceptional items

Also refer NOPAT sheet

Extended Dupont Analysis

Return on Equity

Profit After Tax

Equity

320,505.23

Profit After Tax

Sales

1,724.88
35,297.21

4.89%

Asset Turnover Ratio

Sales
Total Assets

35,297.21
448,787.82

7.87%

Leverage

Total Assets
Total Equity

448,787.82
320,505.23

140.03%

Profit margin

Liquidity Ratios
Amounts in Rs. Lacs
Ratio

Formula

2012-2013

2011-12

A Current Ratio

Total Current Assets

Total Current Liabilities

117,201.53
55,314.88

2.12 : 1

153,427.03
53,203.15

2.884 : 1

B Quick Test Ratio

Current Assets- Inventory

Current Liabilites

116,716.67
55,314.88

2.11 : 1

153,001.74
53,203.15

2.876 : 1

C Inventory Turnover Ratio

Sales
Inventory

35,297.21
484.86

28,127.97
425.29

66.14 Times

Inventory Holding Period

No of days in a year
Inventory Turnover Ratio

Debtors Turnover Ratio

Sales Turnover
Sundry Debtors

Debtors Holding Period

No of days in a year
Debtors Turnover Ratio

365
72.80
35,297.21
9,305.03
365
3.79

72.80 Times

5.01 Days

3.79 Times

96.22 Days

365
66.14
28,127.97
6,249.50
365
4.50

5.52 Days

4.50 Times

81.10 Days

Solvency Ratios
Amounts in Rs. Lacs
Ratio

Formula

2011-12

2011-12

A Debt to equity ratio

Total Borrowings
Sharholders' Funds

there are no loans taken by the company. Hence this ratio is not applicable to Fortis Healthcare

B Liabilities to Equity Ratio

Total Liabilities.
Sharholders' Funds

447,826.41
320,505.23

1.40 : 1

449,749.23
320,460.17

1.40 : 1

C Leverage

Total Assets
Total Equity

447,826.41
320,505.23

1.40 : 1

449,749.23
320,460.17

1.40 : 1

D Interest Coverage Ratio

PBIT(from pg.29)
Interest Expense

(2,462.89)
13,386.47

(0.18) times

(734.67)
10,293.40

(0.07) times

ortis Healthcare

Capital Market Ratios

Amounts in Rs. Lacs
Ratio

Formula

2011-12

2010-11

A Earnings Per Share

(a) Basic
(b) Diluted

0.43
0.43

4.97
4.97

C Price Earnings Ratio

Market Price
Earnings Per Share

466.1
0.43

D Dividend Yield Ratio

Dividend per Share

Market Price

0
466.1

1,083.95

0.00%

409.9
4.97

82.47

0
409.9

0.00%